Business Wire

Lumen Partners With UK's top PT Harry Jameson to Raise Awareness on Metabolic Health

9.3.2021 16:20:00 EET | Business Wire | Press release

Share

Lumen, the creators of the world's first metabolism measurement device through the breath, have teamed up with the UK's top personal trainer, Harry Jameson, to raise awareness on metabolic health for March Metabolism Awareness Month.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210309005629/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

Lumen metabolism tracking device and personalised nutrition (Photo: Lumen)

Harry is available for expert commentary on training to improve your metabolism.

"Having the ability to move between energy sources (fat and carbohydrates) is extremely important. It is a measure of your metabolic health and I’ve been working hard over the past two months to improve mine.

Using Lumen to track whether my diet, fasting or even training is pushing my metabolism in the right direction has been both fascinating from a coaches perspective and incredibly insightful from a user/customer perspective. I love how lumen keeps me both accountable and consistent with my behaviours and getting personalised nutrition plans really helps take a mental load off my shoulders in my busy schedule," says personal trainer Jameson.

Lumen and Jameson are also working together to emphasise the importance of metabolic health in combating metabolic syndrome. In the UK, 1 in 3 adults over the age of 50 will suffer from metabolic disease which is a combination of diabetes, high blood pressure (hypertension) and obesity.

The power to move away from metabolic disease by training your metabolism to switch efficiently between carbs and fats as a fuel source is a term called metabolic flexibility.

"If we feed and train our metabolism, we can process our food more efficiently - you may be able to eat a slice of pie and use it for energy faster if you have a good metabolism. We are merely training our body to use fuel sources properly- an innate mechanism. There's really no need to crash diet , if we take care of our metabolism everything else follows", says PHD in nutrition and founder of Lumen, Michal Mor.

According to research data obtained by 1 million metabolism measurements through the Lumen device, users are able to:

  • Lose an average of 0.5 kg or 1.5 pounds of weight per week on a consistent basis
  • Improve their metabolic flexibility by 66%
  • Improve fasting windows to 12 hours daily
  • Increase their daily movement by 1000 steps

Research also (Calcada et al, Gormsen et al) finds that metabolic flexibility has a profound role in assessing a person's long-term health. People with good metabolic flexibility:

  • Are at lower risk of developing obesity, diabetes and metabolic disorders.
  • Are in a better position to gain muscle and perform better during workouts;
  • Find it easier to lose weight and maintain it

Lumen is the only device in the world to measure your metabolism through the breath and track your metabolic health to prevent diseases born out of poor nutrition.

Based on the traditional RER test which was once available only in hospitals or clinics, is accessible to anyone and anywhere for the first time-revolutionizing the way we approach weight loss, fitness and healthy nutrition decision making.

Through the co2 in your breath, Lumen measures your metabolism and provides an insight into whether you're burning fats or carbs in less than a minute.

Scientific Validation

Lumen can provide numerous insights about the metabolism of an individual, as well as valuable scientific data to increase knowledge of metabolic flexibility and nutrition. In a study conducted by San Francisco State University, Lumen has been validated to meet the gold standard for metabolic measurement.

Availability

The Lumen device is available at Lumen.me, currently priced at £299.

The device comes equipped with a travel case, charging dock, USB-C Cable, and Premium Customer Support. Users can download the app for free on the Apple App Store and on Google Play.

For media: images, video and fact sheet can be found in the press kit here.

About Lumen

Lumen helps people improve their health and fitness through technology on the forefront of personalized nutrition and metabolism. Conceived and designed by twin sisters, physiology PhDs and Ironman winners, Lumen harnesses the power of our breath to measure metabolism, which is closely linked to weight, fitness and personal health. The Lumen device measures metabolism in a single breath, in less than a minute, which previously was only possible through an hour-long lab test. Available at Lumen.me, Lumen devices ship globally, with the app available on the Apple App Store and Google Play. Lumen is headquartered in Israel, with offices in the United States.

[1] Sources: The role of low-grade inflammation and metabolic flexibility in aging and nutritional modulation thereof: A systems biology approach. Available via: https://www.sciencedirect.com/science/article/pii/S0047637414000050. Last accessed 5 May 2020.

[2] Source: Estradiol acutely inhibits whole body lipid oxidation and attenuates lipolysis in subcutaneous adipose tissue: a randomized, placebo-controlled study in postmenopausal women. Available via:https://eje.bioscientifica.com/view/journals/eje/167/4/543.xml

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Media contact: Kyla Blumenfeld, press@lumen.me

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

U.S. FDA Grants Priority Review to BeOne Medicines’ TEVIMBRA in First-Line HER2+ GEA29.4.2026 13:00:00 EEST | Press release

BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced that the U.S. Food and Drug Administration (FDA) has granted Priority Review to a supplemental Biologics License Application (sBLA) for TEVIMBRA® (tislelizumab) in combination with ZIIHERA® (zanidatamab) and chemotherapy for the first-line treatment of unresectable locally advanced/metastatic HER2-positive (HER2) gastric, gastroesophageal junction, or esophageal adenocarcinoma. The FDA has also granted Breakthrough Therapy Designation to the regimen of ZIIHERA in combination with fluoropyrimidine- and platinum-containing chemotherapy, with and without TEVIMBRA, in this indication. Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors, BeOne Medicines, said: “HERIZON‑GEA‑01 has the potential to shift the treatment paradigm in this historically difficult-to-treat disease, with the TEVIMBRA-containing arm demonstrating an unprecedented 26-month survival benefit. The FDA’s Prior

European Commission (EC) Approves Henlius and Organon’s POHERDY ® (pertuzumab), the First Approved Biosimilar to PERJETA (pertuzumab) in Europe29.4.2026 12:30:00 EEST | Press release

Shanghai Henlius Biotech, Inc. (2696.HK), and Organon (NYSE: OGN) today announced the European Commission (EC) has granted marketing authorization for POHERDY® (pertuzumab) 420 mg/14 mL injection for intravenous use, the first and only approved biosimilar to PERJETA (pertuzumab) in Europe, for all indications of the reference product.1 This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260429686426/en/ “As the first, and currently the only, pertuzumab biosimilar in Europe, the EC’s approval of POHERDY marks an important milestone in expanding access to treatments for patients with certain HER2-positive breast cancers, particularly as breast cancer is the most commonly diagnosed cancer among women in the European Union,” said Joe Azzinaro, Vice President, Global Commercial Lead Biosimilars, at Organon.2,3 “Organon’s growing global portfolio of biosimilars reinforces our ongoing commitment to supporting the sustainability of healt

CORRECTING and REPLACING Yoshihiro Shimamura, a Leading Investor in Japan’s Entertainment Industry, to Host Workshop at the 2026 Cannes Film Festival29.4.2026 11:49:00 EEST | Press release

Headline of release dated April 27, 2026 should read: Yoshihiro Shimamura, a Leading Investor in Japan’s Entertainment Industry, to Host Workshop at the 2026 Cannes Film Festival The updated release reads: YOSHIHIRO SHIMAMURA, A LEADING INVESTOR IN JAPAN’S ENTERTAINMENT INDUSTRY, TO HOST WORKSHOP AT THE 2026 CANNES FILM FESTIVAL Shimamura Yoshihiro Film Planning Inc. (Head Office: Osaka, Japan; CEO: Yoshihiro Shimamura), a company engaged in film production and investment, will host a workshop in France during this year’s Cannes Film Festival, as part of its commitment to further advancing the entertainment industry. The company invests in leading entertainment-related businesses in Japan and places strong emphasis on long-term value creation. It identifies the cultural and entertainment sectors as high-growth areas and is actively involved in international co-productions as a core part of its film production activities. As a recent investment, the company acquired 2,000,000 shares of

Andreas Goppelt Appointed Managing Director of OrphaCare29.4.2026 11:27:00 EEST | Press release

OrphaCare, a global specialist for the development and marketing of medical devices for drug delivery and part of the AOP Health Group, has appointed Andreas Goppelt as its new Managing Director, succeeding Georg Fischer. In this role, the seasoned medical device expert will focus on broadening the company’s strategic scope and driving its next phase of growth. OrphaCare plays a key role in supporting AOP Health’s integrated therapies approach, and the Group’s long-term expansion. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260429303533/en/ Portrait Andreas Goppelt, Managing Director OrphaCare (copyright: AOP Health/Studio Koekart) Andreas Goppelt brings more than 25 years of leadership experience across MedTech, biotechnology and the pharmaceutical industry. He has a proven track record of driving innovation, scaling global organizations, and delivering growth in highly regulated healthcare environments. In his new role,

The Jury Has Been Announced for the Third Edition of the Reply AI Film Festival, Dedicated to the Best Short Films Generated With Artificial Intelligence29.4.2026 11:00:00 EEST | Press release

Reply [EXM, STAR: REY], an international group specialized in creating new business models enabled by AI and long committed to guiding younger generations in exploring emerging technologies, presents the jury of the third edition of the Reply AI Film Festival, the international competition aimed at creatives, directors, and filmmakers who want to challenge themselves in producing short films created using Artificial Intelligence tools. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260429288361/en/ “Imaginatio Nova” is the theme of the 2026 edition, an invitation to explore a new phase of imagination, where human creativity is renewed through technology. Leading the jury will be Gabriele Salvatores, Italian director and screenwriter known for films such as Nirvana, Siberian Education, and Napoli - New York, and Academy Award® winner for Best Foreign Language Film with Mediterraneo. Joining him on the panel for the third edit

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye